Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.
Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.
Ask the Doctor Question: I have to start my first therapy soon and living in Germany. First diagnosis in 2015 and until now, watch and wait. ighv mutated, trisomie12, birc3 mutation.
This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.
While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.
Ibrutinib and Venetoclax have as we like to say at the CLL Society orthogonal or complementary mechanisms of action. Ibrutinib inhibits chronic lymphocytic leukemia or CLL cells’ proliferation and gets the cancer cells out of their protective niches in the nodes and bone marrow and into the blood stream where they are easier to kill.
West Nile season started early, and CLL weakens immunity even before treatment. Avoiding mosquito bites is your best protection.
Patients with CLL and high-risk genetic factors had better outcomes on acalabrutinib-venetoclax combination therapies than on chemoimmunotherapy.
A large prospective collaborative trial tests whether adding pirtobrutinib to standard R-CHOP improves outcomes in Richter transformation.
